Form 4: NeueHealth Insider Edward Mathers Acquires Warrants Under Warrantholders Agreement

Director Edward Mathers reports acquisition of warrants to purchase NeueHealth, Inc. common stock, pursuant to a Warrantholders Agreement.

Summary

• On April 8, 2024, Edward T. Mathers, a director of NeueHealth, Inc., acquired warrants to purchase common stock.
• The warrants are issued pursuant to a Warrantholders Agreement dated April 8, 2024, and an amended Credit Agreement.
• Mathers acquired warrants for 123,729 shares and 371,187 shares, with an exercise price of $0.01 per share.
• The warrants will be exercisable after the Closing Date, which is the first business day following the 10-day period after the distribution of a letter to shareholders as required by the NYSE Listed Company Manual.
• The warrants expire five years after the Closing Date.
• Mathers disclaims beneficial ownership of the securities held by NEA 17 and NEA 18 VGE, except to the extent of his pecuniary interest.

Sentiment

Score: 7

Explanation: The document is a standard regulatory filing detailing insider transactions. It doesn't contain overtly positive or negative information, but the acquisition of warrants by a director could be seen as a moderately positive signal.

Future Outlook

The warrants will be exercisable at any time after issuance and prior to the close of business on the fifth anniversary of the Closing Date.

Industry Context

This filing reflects insider activity related to warrant acquisition, which is a common practice in corporate finance, particularly in connection with credit agreements and shareholder agreements. It provides transparency into the holdings of company insiders.

Comparison to Industry Standards

• Warrant issuances are a common practice in corporate finance, often used in conjunction with debt financing or as incentives for key stakeholders.
• The terms of the warrants, such as the exercise price and expiration date, are typical for such instruments.
• Similar transactions can be observed in other publicly traded companies, where warrants are issued to lenders or investors as part of financing agreements.

Stakeholder Impact

• The warrant issuance could potentially dilute existing shareholders if the warrants are exercised in the future.
• The transaction provides transparency to shareholders regarding insider holdings.

Next Steps

• The warrants will be issued on the Closing Date, which is the first business day following the conclusion of the 10 calendar day period after the distribution of the letter required to be mailed by the Issuer to its shareholders pursuant to Section 312.05 of the NYSE Listed Company Manual.

Key Dates